Ariflo COPD Long-Term Efficacy Studies Should Use Active Controls – Cmte.

GlaxoSmithKline's long-term efficacy studies for Ariflo in chronic obstructive pulmonary disease should be designed as non-inferiority trials with active controls, members of FDA's Pulmonary-Allergy Drugs Advisory Committee suggested Sept. 5